Antibiotic resistance

INNO-SAFE-LIFE

UNIVERSITATEA
DE MEDICINĂ ŞI FARMACIE
„VICTOR BABEŞ" DIN TIMIŞOARA

Co-funded by
the European Union

UNIVERSITÀ DELLA CALABRIA

SPU
Slovenská poľnohospodárska univerzita v Nitre

UNIVERSITATEA DE MEDICINĂ ŞI FARMACIE CAROL DAVILA

FAVISAN

Introduction and Historical Overview

Discovery era (1928–1970): exponential antibiotic development.

Resistance emergence: appeared within years of clinical introduction.

Post-antibiotic threat: WHO (2020) recognizes resistance as a top 10 global health risk.

Antibiotic resistance = **natural evolutionary phenomenon** accelerated by human misuse.

Bacterial adaptation to antibiotics is as old as microbial evolution itself. What's changed is anthropogenic pressure — overuse, misuse, and environmental contamination have accelerated selection dynamics.

Global Burden

>1.2 million deaths/year directly attributable to resistant infections (Lancet, 2022).

Projected 10 million deaths/year by 2050 if unchecked.

Economic impact: **$100 trillion cumulative cost** projected.

High resistance rates: *E. coli*, *K. pneumoniae*, *S. aureus*, *M. tuberculosis*.

Antibiotic resistance represents both a biomedical and economic crisis. Beyond mortality, prolonged hospital stays and therapeutic failures strain healthcare systems globally.

Mechanistic Basis of Resistance

Enzymatic degradation of antibiotic.

Target modification or protection.

Reduced intracellular accumulation (efflux, permeability).

Metabolic pathway alteration.

Biofilm-mediated tolerance.

Resistance mechanisms operate at molecular and community levels. Each class corresponds to a specific biochemical adaptation — understanding these mechanisms informs new therapeutic strategies.

Enzymatic Inactivation

β-lactamases: hydrolyze β-lactam ring (e.g., TEM, SHV, CTX-M).

Carbapenemases: KPC, NDM, OXA-48 families.

Aminoglycoside-modifying enzymes: acetyl-, phospho-, and nucleotidyltransferases.

Chloramphenicol acetyltransferase (CAT) – modifies antibiotic structure.

The enzymatic destruction or modification of antibiotics is the most direct mechanism of resistance. β-lactamases have diversified rapidly through plasmid exchange and global dissemination.

Target Site Modification

Ribosomal mutations: alter antibiotic binding (e.g., macrolides, tetracyclines).

DNA gyrase/topoisomerase changes: fluoroquinolone resistance (gyrA, parC mutations).

Cell wall target alteration: MRSA's mecA gene → PBP2a (low β-lactam affinity).

rRNA methyltransferases (erm genes): macrolide-lincosamide resistance.

Target modification protects essential cellular machinery without compromising function. Horizontal acquisition of resistance determinants like *mecA* exemplifies the modularity of bacterial evolution.

Efflux Pumps and Reduced Permeability

Efflux systems: actively export antibiotics (e.g., AcrAB-TolC in *E. coli*).

Multidrug efflux families: RND, MFS, ABC, SMR.

Porin loss (e.g., OmpF/OmpC) decreases permeability in Gram-negatives.

Biofilm matrix: limits diffusion, creating phenotypic tolerance.

Efflux pumps confer broad-spectrum resistance by expelling structurally unrelated drugs. When combined with porin loss, they create formidable intrinsic resistance barriers, particularly in Gram-negative pathogens.

Genetic Basis and Horizontal Gene Transfer

Mobile genetic elements (MGEs): plasmids, transposons, integrons.

Horizontal transfer mechanisms:

- **Conjugation:** plasmid-mediated DNA exchange.
- **Transformation:** uptake of free DNA.
- **Transduction:** bacteriophage-mediated transfer.

Integrons capture and express resistance cassettes (class 1–3).

Horizontal gene transfer (HGT) accelerates resistance evolution beyond clonal lineages. Integron–plasmid complexes have created "superbugs" with multi-resistance phenotypes across species boundaries.

Resistome and Mobilome

Resistome: total set of resistance genes (functional + silent).

Mobilome: mobile elements facilitating gene dissemination.

Environmental resistome: soil, wastewater, animal microbiomes.

Anthropogenic pressure expands the resistome via selective enrichment.

Metagenomic studies reveal that environmental microbiomes act as massive gene reservoirs. Human activity mobilizes these genes into pathogens via co-selection and cross-resistance mechanisms.

Biofilms and Persister Cells

Biofilm structure: EPS matrix protects embedded bacteria.

Reduced antibiotic penetration and metabolic dormancy.

Persister cells: non-replicating, transiently tolerant subpopulations.

Associated with chronic infections (e.g., cystic fibrosis, prosthetic devices).

Biofilms complicate treatment by creating microenvironments where antibiotics fail to reach inhibitory concentrations. Persisters are phenotypic variants—not mutants—that can reignite infection post-treatment.

Environmental Dimensions of Resistance

Wastewater effluents: contain antibiotics and resistant bacteria.

Agriculture: veterinary antibiotics select resistance in soil microbiota.

Aquaculture: prophylactic antibiotic use → aquatic resistome amplification.

Pharmaceutical manufacturing: hotspots for multi-resistant strains.

The environment serves as both sink and source. Effluent discharge and animal husbandry practices promote the selection and horizontal transfer of resistance genes into natural microbial communities.

One Health Perspective

Recognizes interconnectedness of **humans, animals, environment.**

Antimicrobial use in livestock: 70% of global antibiotic production.

Cross-domain transmission: zoonotic bacteria carrying human resistance genes.

Policy integration: FAO–OIE–WHO collaboration for AMR containment.

A One Health approach is essential since resistance genes traverse ecological boundaries. Integrated surveillance across human, veterinary, and environmental sectors is the only sustainable mitigation path.

Clinical and Epidemiological Trends

ESKAPE pathogens: Enterococcus faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, Enterobacter spp.

WHO Priority Pathogen List (2021): carbapenem-resistant Enterobacterales, MRSA, VRE.

Global hotspots: South Asia, Sub-Saharan Africa, Eastern Europe.

Rise of **pan-resistant "superbugs."**

These priority pathogens are responsible for most nosocomial and community-acquired resistant infections. Epidemiological surveillance shows alarming convergence of resistance across continents.

Molecular Diagnostics and Surveillance

Phenotypic assays: MIC, disk diffusion, E-test.

Genotypic methods: PCR, qPCR, WGS, metagenomics.

Rapid diagnostics: MALDI-TOF, CRISPR-based detection.

Global surveillance platforms: GLASS (WHO), EARS-Net, NARMS.

Early detection is crucial for containment. Molecular methods identify resistance genes before phenotypic manifestation, enabling preemptive clinical and policy interventions.

Emerging Threats: Novel Resistance Mechanisms

mcr genes (mcr-1 to mcr-10): plasmid-mediated colistin resistance.

blaNDM, blaKPC: global carbapenemase dissemination.

VanA/VanB clusters: vancomycin resistance in enterococci.

Heteroresistance: subpopulations exhibiting transient high resistance.

New resistance genes emerge continuously. The plasmid-mediated colistin resistance gene mcr-1 (2015) exemplifies the speed at which last-resort antibiotic defenses can be compromised globally.

Antibiotic Resistance and the Microbiome

Gut microbiome: key reservoir for resistance genes (ARGs).

Antibiotic exposure → dysbiosis → expansion of resistant taxa.

Horizontal gene transfer within gut ecosystem.

Collateral impact: reduced colonization resistance to pathogens (e.g., *C. difficile*).

The gut microbiota acts as a dynamic resistome incubator. Antibiotic therapy alters microbial ecology, facilitating horizontal gene flow and re-infection susceptibility.

Strategies for Containment and Mitigation

Antimicrobial stewardship programs (ASPs): optimized prescription.

Infection prevention: hygiene, vaccination, surveillance.

Alternative therapeutics: phage therapy, probiotics, anti-quorum sensing agents.

R&D incentives: novel antibiotics, non-traditional antimicrobials.

Containment requires systemic interventions — rational prescribing, global coordination, and innovation. Stewardship aligns clinical care with evolutionary principles to slow resistance selection.

Innovation in Therapeutics

β-lactamase inhibitors: clavulanic acid, avibactam.

CRISPR–Cas antimicrobials: precision gene targeting.

Antimicrobial peptides (AMPs): membrane-disrupting alternatives.

Bacteriophage therapy: personalized viral treatments targeting MDR bacteria.

Nanocarrier systems: improved drug delivery, biofilm penetration.

The antibiotic pipeline must evolve beyond conventional small molecules. Synthetic biology and nanotechnology offer innovative therapeutic paradigms to overcome resistance barriers.

Global Governance and Policy

WHO Global Action Plan (2015): coordinated international response.

National AMR Action Plans (NAPs): >140 countries implemented.

Regulatory control: antibiotic bans in feed, prescription-only models.

Surveillance gaps persist in low-resource regions.

Public engagement: behavioral change essential for sustainability.

Policy integration is progressing but uneven. A unified global governance framework must align science, economics, and behavioral interventions to curtail resistance emergence.

Conclusion

Antibiotic resistance = **ecological and evolutionary inevitability**, accelerated by misuse.

Driven by **molecular adaptation, gene mobility, and environmental selection.**

Requires **multilevel response:** scientific innovation, stewardship, and policy integration.

The future depends on **sustaining antibiotic efficacy as a shared global resource.**

Antibiotic resistance symbolizes a collision of evolution and human behavior. Preserving antibiotic utility demands global solidarity — integrating molecular science with ethics and governance.